Dr. Laura Elizabeth Regan, M.D. Dermatology - Dermatopathology Medicare: Accepting Medicare Assignments Practice Location: 1316 Alverser Plz, Midlothian, VA 23113 Phone: 804-379-0116 Fax: 804-379-1088 |
B Thomas Reams, MD Dermatology Medicare: Not Enrolled in Medicare Practice Location: 1507 Huguenot Road, Suite 200, Midlothian, VA 23113 Phone: 804-794-3140 Fax: 804-378-5457 |
Dr. Josephine S Bohannon, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 2306 Robious Station Circle, Midlothian, VA 23113 Phone: 804-378-3048 Fax: 804-379-5167 |
Ms. Stacy C Romero, PAC Dermatology Medicare: Medicare Enrolled Practice Location: 2306 Robious Station Circle, Midlothian, VA 23113 Phone: 804-378-3048 Fax: 804-378-3264 |
Dr. Erin Gilbert Adams, MD Dermatology Medicare: Medicare Enrolled Practice Location: 2306 Robious Station Cir Ste A, Midlothian, VA 23113 Phone: 804-378-3048 Fax: 804-379-5617 |
News Archive
More than a third of patients with long-term fatigue conditions like Myalgic Encephalomyelitis (ME) believe complementary and alternative medicines (CAMs) are more effective than traditional medicine in treating their illness, research launched at the British Pharmaceutical Conference (BPC) in Manchester reveals.
BMJ News examines details of the WHO Global Code of Practice on the International Recruitment of Health Personnel (.pdf) agreed upon last Friday by member countries during the World Health Assembly (WHA) that "discourages countries from actively recruiting from poor nations facing critical staff shortages."
The International Coordinating Group on vaccine provision for yellow fever has provided 1.4 million vaccine doses for an immunization campaign that starts on Saturday (2 December) to help control an ongoing yellow fever outbreak in Nigeria.
Gilead Sciences, Inc. and GlaxoSmithKline today announced a licensing agreement to commercialize Viread® (tenofovir disoproxil fumarate) for the treatment of chronic hepatitis B (HBV) infection in adults in five countries in Asia. The companies' combined commercialization activities will expand access to Viread for the treatment of HBV, once approved, to patients in Asia where the prevalence in most countries is greater than 8 percent.
› Verified 5 days ago